



Patent Docket P1746R1P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Vanessa Chisholm et al.

Serial No.: 10/714,000

Filed: November 14, 2003

For:

EXPRESSION VECTORS AND

METHODS

Group Art Unit: 1632

Examiner: Not Yet Assigned

Confirmation No: 1570

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 14, 2004

Pam Golden

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

37 CFR §1.97(c) 0

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Filing Date: November 14, 2003

Page 2

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

• after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith. A copy of an International Search Report from a related application is enclosed herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after

Serial No.: 10/714,000

Filing Date: November 14, 2003

the references.

Page 3

June 30, 2003 **(1276 OG 55)**. Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

[] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: October 4, 2004

Cara M. Coburn

Reg. No. 46,631

Telephone No. (650) 467-6222

FORM PTO-1449				U.S. Dept. of Commerce		Atty Docket No.			Serial No.	
			4	PRON	and Trademark Office	P17461		10,	/714,000	
LICT	0E D'	SCLOSURES CITED B	V ADDI ICANT		1	Applic				
LIST	OF DI	SCLOSURES CITED B	YAPPLICANI	2 1 2004		Chisholm et al.			· · · · · · · · · · · · · · · · · · ·	
(U	se sev	eral sheets if necessar	n) \ .	9		Filing Date		1	Group	
			to.			14 Nov 2003			1632	
				TA TOUR SERVICE	ENT DOCUMENTS					
Examiner Initials		Document Number	Date		Name		Class	Subclass	Filing Date	
	*59	6,235,967	22.05.01	Tan et al.					27.03.98	
	*60	6,632,637	14.10.03	McGrew					12.10.00	
				FOREIGN	PATENT DOCUMENT	S				
Examiner Initials		Document Number	Date		Country		Class	Subclass	Translation Yes No	
	61	WO 2004/046340	03.06.04	PCT			· · ·	-		
					ng Author, Title, Date,	Pertinen	t Pages, etc.	<u> </u>		
	i	Ferrari, et al.,	"Chinese Hamst	er Ovary Cells	with Constitutive	ely Expr	essed Sia	idase An	tisense RNA	
·	62	produce Recombinant DNase in Batch Culture with Increased Sialic Acid" <u>Biotechnology and Bioengineering</u> , John Wiley & Sons, Inc. Vol. 60(5):589-595 (Dec 5, 1998) Kaufman, "High Level Production of Proteins in Mammalian Cells" <u>Genetic Engineering</u> , New York and								
	63	Kaufman, "High Level Production of Proteins in Mammalian Cells" Genetic Engineering, New York and London: Plenum Press Vol. 9:155-198 (1987)								
	Petitclerc, et al., "The Effects of Various Introns and Transcription terminators on the efficiency of expression Vectors in Various Cultured Cell Lines and in the Mammary Gland of Transgenic Mice" <u>Journal</u> of Biotechnology, Elsevier Science B.V. Vol. 40:169-178 (1995)									
	65	Weikert, et al., "Engineering Chinese Hamster Ovary Cells to Maximize Sialic Acid Content of Recombinate Glycoporteins" Nature America Inc. 17:1116-1121 (Nov 1999)								
							• •			
					· · · · · · · · · · · · · · · · · · ·				·	
				·						
								. 411 4		
							<u> </u>			
							. <u></u>	. <u> </u>		
									,	
Evenie						Date Cons	idered			
Examin										
*Exami if not	ner: Ir in con	nitial if reference considering formance and not considering the constant of t	lered, whether or r sidered. Include co	not citation is in copy of this form w	onformance with MPEP rith next communication	609; dra	w line throug ant.	gh citation		